Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm looking at short interest from I-broker
That may account for the need for two additional doses, to 28 days.
So I've been watching the short interest throughout the day
HGEN said it would take 12 months to get production at an annual run-rate of 100k vials.
That’s not a good thing, correct. Longer the time to cover the safer the shorter feels?
"DMSC told us continue and you will achieve your primary endpoint"
unfortunately I haven't had that much cooperation from the posters on this board.
It is amazing how many excuses people will give for Nader. People accuse Fauci of being corrupt and in the pocket of Big Pharma even though he has chosen a life of public service instead of making tens of millions in the private sector. Nader meanwhile has shown a consistent pattern of bigtime and smalltime corruptness over the last 30 years. How in the world can a shareholder not have a problem with Nader unjustly enriching himself to the tune of millions? He tells you the stock is going to $100 and then immediately sells for a few dollars. Nader doesn't care about shareholders or patients. Greed is his only motivating factor. And his greed often comes at the expense of CYDY shareholders.
Hit us with something new. Something interesting.
Theft by deception sounds more like opening an account in a fictitious name and writing checks.
Short interest went from 8.5 million shares on April 15th to 7.9 million shares on April 30th.
https://www.nasdaq.com/market-activity/stocks/hgen/short-interest
Not that I'm averse to differing opinions
If you come to wound a company with a life-saving drug to make a few $?
It seems many just want this to be an echo chamber. A savvy investor will always welcome differing viewpoints.
I hadn't heard (or don't recall hearing, anyway) that lenz had a shelf life of about 20 days.
See page 19 of 8-k.
12/43 (28%) for LL+SOC and 7/19 (37%) for placebo+SOC
28% I thought, not 38.
A small part of me worries that 60 day data might look less favorable although that seems unlikely given how great the results were.
But March 29th was 60 days after the last patient was dosed. I think the data reported results through day 60.
I've been wondering about the 60 day secondary end points and why the omission
What can I tell you, Don? The two articles under discussion are both dated today.
Lenzilumab didn't do well with patients in the advanced stage of severe. It actually makes sense since GM-CSF is "upstream". GM-CSF is the cytokine responsible for starting the cytokine storm. Once the cytokine storm is on full blast, it is too late for lenzilumab.
The trial also had less efficacy with patients 85 years old and older. This also makes sense. A person needs a good immune system to reach the age of 85. 85+yo don't experience the cytokine storm much and have done far better than younger age groups.
Lenz's whole study has 54% efficacy but further analysis brings some eyepopping results. Patients who are treated when they have been hospitalized for 2 days or less have 88% efficacy. When patients 85+ and patients in the advanced stage of severe aren't included, efficacy on preventing mechanical ventilation goes up to 296%. The mortality benefit in this same group is 217%.
Naysayers might argue that I am datamining or cherry picking but I disagree. It could have been predicted that the 85+ and advanced stage severe patients wouldn't have efficacy. I think the FDA will give an EUA and give guidance that patients should be administered lenzilumab immediately after being hospitalized. Unfortunately, the 85+ age group might have to be excluded or it could possibly be left up to the physician.
But patients globally need many different drugs
Why lenzilumab patients accepted for a study are really moderate to slightly severe , Why not really sick if drug THAT good?
Those exact quotes are in the March 29th article that Reuters wrote.
https://www.reuters.com/business/healthcare-pharmaceuticals/humanigen-says-drug-improves-ventilator-free-survival-covid-19-patients-2021-03-29/
"We will have some meetings with the FDA over the next few weeks to better understand what will be required to submit an emergency use approval application," Cameron Durrant, the company's CEO, told Reuters...
We are expanding our production and we hope to have enough treatments to be able to treat 100,000 patients over the next 12 months," said CEO Durrant."
That may very well be true. Same song management has been singing for some time now.
Is 2.96-fold efficacy the exact same thing as 296% efficacy?
Premarket is down. That has been a good sign lately.
What is the name of the doctor requesting vials in that letter?
DEBUNKED
I (and everyone else) saw 175mg vials in the Proactive-ish video.
175mg vials touted in the Sunday chit chat
And according to dr Patterson only about 20-25% patients with covid showing higher GM-CSF.
When you insisted CYDY dont have 350 mg vial with leronlimab
Why did they need a special design by NIH and FDA , if they don't even have enough of drug.
But why did they need a special design by NIH and FDA
And lenzilumab has no drug even to use if they need too , per CEO recently ..
" we AIM to have 100,000 doses in 12 months "
this equal to about 33,000 patients , since each need 3 doses.
Also, as someone else mentioned, what happened to the 28 CSP patients? Why no mention of this?
And our phase 3 in combo for MDR 2 and 3 finished in 2018 February , with 81% efficacy , and not one serious side effect , and is not yet approved by USA FDA
I predict I will be a billionaire.
Nope, longs only have to be right once.
How many times have you predicted that?
I am sure that he would tell you that leronlimab was quite efficacious for him.